In 2004, a clinical study was performed that both validated prospectively the association of the variant with greater toxicity and the ability of genetic testing in predicting that toxicity before chemotherapy administration.
In 2005, the FDA made changes to the labelling of irinotecan to add pharmacogenomics recommendations that patients with polymorphisms in UGT1A1 gene, specifically the variant, should perhaps receive reduced drug doses. Irinotecan is one of the first widely-used chemotherapy agents that is dosed for each patient according to his genotype.

1. Introduction of Irinotecan hydrochloride
Irinotecan hydrochloride is yellow crystalline powder or white or off-white crystalline powder. Its systematic name is called (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate hydrochloride (1:1). Irinotecan hydrochloride belongs to product categories of Active Pharmaceutical Ingredients; Antineoplastic; Antitumors for Research and Experimental Use; Biochemistry; Chiral Reagents; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; Irinotecan.

This chemical is a yellow crystalline powder and should be sealed in a cool, dry place at the temperature of 2-8 °C. Besides, its Classification Code is Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug / Therapeutic Agent; Enzyme Inhibitors; Mutation data; Radiation-Sensitizing Agents; Reproductive Effect; Topoisomerase I Inhibitors; Topoisomerase Inhibitors. Irinotecan hydrochloride Solubility is DMSO (50 mg/ml).

2. Properties of Irinotecan hydrochloride
Physical properties about Irinotecan hydrochloride are:
(1)ACD/LogP: 4.18; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): 1.09; (4)ACD/LogD (pH 7.4): 2.53; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 19.89; (7)ACD/KOC (pH 5.5): 3.63; (8)ACD/KOC (pH 7.4): 100.73; (9)#H bond acceptors: 10; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 6; (12)Polar Surface Area: 101.51 Å²; (13)Flash Point: 482 °C; (14)Enthalpy of Vaporization: 132.98 kJ/mol; (15)Boiling Point: 873.4 °C at 760 mmHg; (16)Vapour Pressure: 1.31E-32 mmHg at 25 °C.

3. Structure Descriptors of Irinotecan hydrochloride
You can still convert the following datas into molecular structure:
(1) SMILES: Cl.O=C7OCC=6C(=O)N2C(\c1nc5c(c(c1C2)CC)cc(OC(=O)N4CCC(N3CCCCC3)CC4)cc5)=C/C=6[C@@]7(O)CC
(2) InChI: InChI=1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1
(3) InChIKey: GURKHSYORGJETM-WAQYZQTGSA-N

4. Toxicity of Irinotecan hydrochloride
The toxicity data is as follows:

6. Uses of Irinotecan hydrochloride
Irinotecan hydrochloride is a DNA topoisomerase inhibitor. What's more, Irinotecan hydrochloride is used as DNA topoisomerase inhibitor and antineoplastic. It can inhibitor of DNA topoisomerase I that displays antitumor activity against a range of tumor types.